5 results about "Coagulation system" patented technology

This application discloses a nanovesicle, its preparation method, and its application. The nanovesicle includes a core layer containing hemostatic active ingredients; first, second, third, and fourth intermediate layers (collectively forming a shell); and an outer layer (corona). The first intermediate layer is composed of a pH-sensitive polymer material, sensitive to the absolute value of transmembrane pH difference; the second intermediate layer is composed of a hypoxia-sensitive lipid complex; the third intermediate layer is composed of an osmotic pressure-sensitive phospholipid bilayer, sensitive to the absolute value of transmembrane osmotic pressure difference; the fourth intermediate layer is composed of an inflammatory factor / reactive oxygen species-sensitive hydrogel; and the outer layer is composed of a bifunctional polymer brush possessing both temperature difference response and mechanical difference sensing capabilities. This nanovesicle can respond to multidimensional microenvironmental differences between the intravascular and extravascular sides at the bleeding point, orderly disintegrating and releasing hemostatic active ingredients, providing a feasible technical approach for developing precise hemostasis strategies that do not rely on activation of the systemic coagulation system.

This invention belongs to the field of biomedicine and relates to a procoagulant polypeptide TPTX and its applications. The procoagulant polypeptide TPTX of this invention can exert its procoagulant and hemostatic effects by specifically inhibiting plasmin activity. Experiments have shown that TPTX exhibits significant dose-dependent procoagulant and hemostatic effects in ferric chloride-induced mouse carotid artery thrombosis models, mouse liver hemorrhage models, mouse tail hemorrhage models, and mouse saphenous vein hemorrhage models, with effects superior to the positive control drug 6-aminocaproic acid. Simultaneously, TPTX can reduce the area of ​​atorvastatin-induced cerebral hemorrhage in zebrafish and improve their motor dysfunction. Mechanistic studies show that TPTX has an inhibitory constant Ki of 17.76 nM on plasmin and has no significant effect on the activity of seven other key serine proteases in the coagulation system, demonstrating a clear target and high selectivity. The procoagulant polypeptide of this invention can be used to prepare hemostatic drugs, possessing the advantages of high efficiency, clear target, and high selectivity, with broad prospects for clinical application.

The application discloses an oil-in-water probiotic emulsion based on a heterologous protein complex coagulation system and a preparation method and application thereof. The preparation method is as follows: first, a mixed solution of lactoferrin and bone bridge protein is prepared, and then the solution is stirred and dissolved at room temperature to hydrate; the pH is adjusted to 4.6-5.4 to obtain an aqueous phase; probiotic powder is dispersed in medium-chain triglyceride to obtain an oil phase; and the aqueous phase and the oil phase are mixed and homogenized to obtain the oil-in-water probiotic emulsion. The application has the advantages of simple preparation process, low cost, no need to add an emulsifier, no need to heat and add a crosslinking agent for strengthening the stability of the aqueous phase, high embedding rate of the oil-in-water emulsion probiotic, double protection, improved gastrointestinal tolerance and environmental resistance of the probiotic in the emulsion, and prolonged shelf life of the product, which expands the application of the probiotic and the protein in the food field.

This invention discloses a method for surface-modified biomaterials and a modified pericardial material, relating to the field of biomedical materials technology. The method includes the following steps: S1, providing animal pericardial material cross-linked with glutaraldehyde; providing a bridging molecule containing a first bridging group and a second bridging group, and a phosphorylcholine polymer with a third bridging group at its end; binding the first bridging group to an aldehyde group on the surface of the pericardial material via a first covalent reaction; binding the second bridging group to the third bridging group via a second covalent reaction, thereby achieving grafting of the phosphorylcholine polymer onto the material surface; the first covalent reaction and / or the second covalent reaction include Schiff base formation and reductive amination processes. The modified pericardial material prepared in this application introduces a phosphorylcholine biomimetic coating, which can improve blood compatibility on the material surface, reduce activation of the coagulation system and platelet adhesion, and inhibit the initiation of calcium ion deposition on the material surface, while exhibiting high safety.

The application provides a kind of for heart death after organ acquisition perfusion fluid and its application, belong to medical technical field.The application is used for heart death after organ acquisition perfusion fluid, including the following components: thrombolytic drug, vasodilator, albumin, dexamethasone sodium phosphate, low molecular weight heparin sodium and lactated Ringer's solution.The organ acquisition perfusion fluid of the application can effectively remove the thrombus formed by coagulation system activation, reduce vasospasm caused by warm ischemic injury and tissue cell edema in the process of perfusion, which can effectively improve the quality and function of the acquired organ, increase the utilization rate of the organ, and has clinical transformation application prospect.